Aquestive rises on US licensing deal for seizure drug with Eton Pharma
14/10/2026 13:01
BUZZ-Aquestive rises on US licensing deal for seizure drug with Eton Pharma ** Aquestive Therapeutics AQST.O shares gain 4.3% to $4.87 premarket
** The drugmaker says it licensed exclusive US rights to its Libervant to Eton Pharmaceuticals ETON.O
** The seizure treatment is expected to launch in April 2027, subject to final approval
** Libervant, a dissolvable diazepam film placed inside the cheek, is designed for people who experience clusters of seizures; can offer alternative to nasal sprays, rectal medicines
** Won FDA nod for patients aged two to five years in April
** FDA reviewing application to expand usage to children ages 6 to 11; decision expected before April
** Stock down 27% YTD
(Reporting by Padmanabhan Ananthan)
Recent news on Aquestive Therapeutics
See all newsBrief: Aquestive Therapeutics Announces FDA Acceptance Of Anaphylm™ NDA Resubmission And PDUFA Goal Date Of March 16, 2027
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Aquestive rises on US licensing deal for seizure drug with Eton Pharma